| Phase 14 trials · 1 met primary |
|
Phase 1
|
NCT05052528 |
Sep 2021 → May 2027 expected |
relapsed/refractory diffuse large B-cell lymphoma |
University of California, Davis |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04007029 |
Oct 2019 → Aug 2026 overdue |
chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, primary mediastinal large B-cell lymphoma |
Jonsson Comprehensive Cancer Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT03696030 |
Aug 2018 → Jan 2027 expected |
HER2 positive breast carcinoma, malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain |
City of Hope Medical Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT03233854 |
Sep 2017 → Jun 2023 overdue |
B-cell acute lymphoblastic leukemia |
Stanford University |
Active not recruiting
|
Met primary
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT03277729 |
Dec 2017 → Mar 2024 overdue |
Richter transformation, central nervous system non-hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +4 |
Fred Hutchinson Cancer Center |
Active not recruiting
|
No outcome recorded
|
| Comparator or background therapy3 trials |
|
Phase 0
|
NCT05800405 Background |
Jul 2023 → Jan 2027 expected |
diffuse large B-cell lymphoma |
City of Hope Medical Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06854159 Background |
Aug 2025 → Oct 2028 expected |
diffuse large B-cell lymphoma |
University of California, Davis |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05202782 Background |
Mar 2022 → Oct 2026 expected |
T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma with chronic inflammation, high grade B-cell lymphoma, high-grade B-cell lymphoma double-hit/triple-hit +4 |
Northwestern University |
Active not recruiting
|
No outcome recorded
|